It used to be thought that it would be physiologically impossible to climb Mount Everest with or without oxygen. In 1953 Hillary and Tenzing proved that it was possible to reach the summit with oxygen and in 1978 Messner and Habeler demonstrated it was possible without oxygen.
Although Everest has not changed, and we now have a better understanding of acclimatisation, improved climbing equipment, and established routes, it would therefore seem logical that climbing Everest might have become an altogether less deadly activity.
However, this year the unofficial body count on Mount Everest has reached 15, the most since the disaster of 1996 when 16 people died, eight in one night following an unexpected storm.
The death rate on Mount Everest has not changed over the years, with about one death for every 10 successful ascents. For anyone who reaches the summit, they have about a 1 in 20 chance of not making it down again.
So why are there so many people dying on Mount Everest? And more importantly, can we reduce this number?
The main reasons for people dying while climbing Mount Everest are injuries and exhaustion. However, there is also a large proportion of climbers who die from altitude related illness, specifically from high altitude cerebral oedema (HACE) and high altitude pulmonary oedema (HAPE).
This year, the author was on the north side of Everest as the doctor on the Everestmax expedition (www.everestmax.com) and was shocked by both the amount of altitude related illness and the relative lack of knowledge among people attempting Everest.
He writes: "On our summit attempt we were able to help with HAPE at 7000 metres, but higher up the mountain we passed four bodies of climbers who had been less fortunate. The last body we encountered was of a Frenchman who had reached the summit four days earlier but was too exhausted to descend. His best friend had tried in vain to get him down the mountain, but they had descended only 50 metres in six hours and he had to abandon him."
"Some people believe that part of the reason for the increase in deaths is the number of inexperienced climbers, who pay large sums of money to ascend Everest," he says. "In my view, climbers are not climbing beyond their ability but instead beyond their altitude ability. Unfortunately it is difficult to get experience of what it is like climbing above Camp 3 (8300 metres) without climbing Everest. Climbers invariably do not know what their ability above 8300 metres is going to be like."
He suggests that climbers need to think less about 'the climb' and more about their health on the way up.
No matter what the affliction, whether it be HACE, HAPE, or just exhaustion, the result is invariably the same – the climber starts to climb more slowly, he explains. If you are too slow this means that something is wrong and your chances of not making it off the mountain are greatly increased. But with the summit in sight this advice is too often ignored.
When the author visited the French consulate in Kathmandu to confirm the Frenchman's death, the consul, not a climbing or an altitude expert, shook his head and said, "He didn't reach the summit until 12.30; that is a 14 hour climb – it is too long."
Emma Dickinson | EurekAlert!
Rising CO2 has unforeseen strong impact on Arctic plant productivity
21.02.2019 | Max-Planck-Institut für Meteorologie
Scientists Create New Map of Brain’s Immune System
18.02.2019 | Universitätsklinikum Freiburg
An international research team including astronomers from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has combined radio telescopes from five continents to prove the existence of a narrow stream of material, a so-called jet, emerging from the only gravitational wave event involving two neutron stars observed so far. With its high sensitivity and excellent performance, the 100-m radio telescope in Effelsberg played an important role in the observations.
In August 2017, two neutron stars were observed colliding, producing gravitational waves that were detected by the American LIGO and European Virgo detectors....
Up to now, OLEDs have been used exclusively as a novel lighting technology for use in luminaires and lamps. However, flexible organic technology can offer much more: as an active lighting surface, it can be combined with a wide variety of materials, not just to modify but to revolutionize the functionality and design of countless existing products. To exemplify this, the Fraunhofer FEP together with the company EMDE development of light GmbH will be presenting hybrid flexible OLEDs integrated into textile designs within the EU-funded project PI-SCALE for the first time at LOPEC (March 19-21, 2019 in Munich, Germany) as examples of some of the many possible applications.
The Fraunhofer FEP, a provider of research and development services in the field of organic electronics, has long been involved in the development of...
For the first time, an international team of scientists based in Regensburg, Germany, has recorded the orbitals of single molecules in different charge states in a novel type of microscopy. The research findings are published under the title “Mapping orbital changes upon electron transfer with tunneling microscopy on insulators” in the prestigious journal “Nature”.
The building blocks of matter surrounding us are atoms and molecules. The properties of that matter, however, are often not set by these building blocks...
Scientists at the University of Konstanz identify fierce competition between the human immune system and bacterial pathogens
Cell biologists from the University of Konstanz shed light on a recent evolutionary process in the human immune system and publish their findings in the...
Laser physicists have taken snapshots of carbon molecules C₆₀ showing how they transform in intense infrared light
When carbon molecules C₆₀ are exposed to an intense infrared light, they change their ball-like structure to a more elongated version. This has now been...
11.02.2019 | Event News
30.01.2019 | Event News
16.01.2019 | Event News
22.02.2019 | Physics and Astronomy
22.02.2019 | Materials Sciences
22.02.2019 | Life Sciences